HIKAL LIMITED Valuation
HIKAL · Healthcare · Current price ₹200.49
Is HIKAL LIMITED undervalued?
DocStoX estimates the fair value of HIKAL LIMITED at ₹145 per share, versus the current market price of ₹200. That puts the stock about -27.6% above our fair-value estimate, which we read as "Expensive". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 2 independent methods: Residual income (₹85), Analyst target (₹300). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹85 (bear) to ₹145 (base) to ₹300 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Valuation multiples
HIKAL LIMITED trades at a P/E of -74.9x and a P/B of 2.3x, with a dividend yield of 0.3%. Multiples are most useful compared against the company's own history and its sector peers — see the peer comparison for context.
Understand the ratios
More on HIKAL LIMITED
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.